Shakthi Harikrishnan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shakthi Harikrishnan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Renukadevi Jeyavelkumaran
Department of Pharmaceutics, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India
2 shared publications - Jayasri Bantaram
Department of Pharmaceutics, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Chennai, India
1 shared publication - Mridula Dhanapal Saravanan
Department of Pharmaceutics, Saveetha College of Pharmacy Saveetha Institute of Medical and Technical Sciences (SIMATS) Chennai India
1 shared publication - Nimithasree Keerthivasan
Department of Pharmaceutics, Saveetha College of Pharmacy Saveetha Institute of Medical and Technical Sciences (SIMATS) Chennai India
1 shared publication - Sandhya Ravishankar
Department of Pharmaceutics, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Chennai, India
1 shared publication - Sanjay Valliappan
Department of Pharmaceutics, Saveetha College of Pharmacy Saveetha Institute of Medical and Technical Sciences (SIMATS) Chennai India
1 shared publication
Latest Publications
- Open Access
- 21 May 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 01_Special (19) , 994
BiP/GRP78 and Unfolded Protein Response in Parkinson’s Disease: Mechanisms, Therapeutic Potential, and Future Directions
Parkinson’s disease (PD) is a progressive neurodegenerative illness characterized by the buildup of misfolded alpha-synuclein in Lewy bodies and the loss of dopaminergic neurons in the substantia nigra. The unfolded protein response (UPR) and endoplasmic reticulum (ER) stress have been implicated in the pathophysiology of Parkinson’s disease (PD) in recent research.BiP/GRP78, an ER-resident chaperone, serves as a central regulator of the UPR by sensing misfolded proteins and modulating three primary stress sensors: PERK, IRE1, and ATF6. While BiP initially acts protectively by restoring ER homeostasis, its sustained activation may lead to maladaptive UPR signaling and neuronal apoptosis. Experimental models have demonstrated that agents such as salubrinal can modulate BiP levels and UPR activity, offering neuroprotection. Moreover, small molecules targeting BiP interactions or its ATPase activity are emerging as potential therapeutics. However, challenges such as blood–brain barrier penetration, tissue-specific effects, and long-term safety must be addressed. Future strategies may include targeted delivery systems, combination therapies involving autophagy modulation, and personalized treatment guided by BiP expression or genomic profiling. This review outlines the dual role of BiP in PD and discusses its therapeutic implications, highlighting the need for precise modulation to maximize clinical benefits while minimizing risks.
- 21 May 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 01_Special (19) , 994
Open AccessBiP/GRP78 and Unfolded Protein Response in Parkinson’s Disease: Mechanisms, Therapeutic Potential, and Future Directions
Parkinson’s disease (PD) is a progressive neurodegenerative illness characterized by the buildup of misfolded alpha-synuclein in Lewy bodies and the loss of dopaminergic neurons in the substantia nigra. The unfolded protein response (UPR) and endoplasmic reticulum (ER) stress have been implicated in the pathophysiology of Parkinson’s disease (PD) in recent research.BiP/GRP78, an ER-resident chaperone, serves as a central regulator of the UPR by sensing misfolded proteins and modulating three primary stress sensors: PERK, IRE1, and ATF6. While BiP initially acts protectively by restoring ER homeostasis, its sustained activation may lead to maladaptive UPR signaling and neuronal apoptosis. Experimental models have demonstrated that agents such as salubrinal can modulate BiP levels and UPR activity, offering neuroprotection. Moreover, small molecules targeting BiP interactions or its ATPase activity are emerging as potential therapeutics. However, challenges such as blood–brain barrier penetration, tissue-specific effects, and long-term safety must be addressed. Future strategies may include targeted delivery systems, combination therapies involving autophagy modulation, and personalized treatment guided by BiP expression or genomic profiling. This review outlines the dual role of BiP in PD and discusses its therapeutic implications, highlighting the need for precise modulation to maximize clinical benefits while minimizing risks.
- 20 March 2026
- Published by Wiley in Peptide Science
- Vol. 118 (3) , e70027
Engineering Peptides for Oral Delivery: Structural Design, Barrier Modulation, and Emerging Therapeutic Technologies
Oral delivery of peptide therapeutics remains a major challenge due to extensive enzymatic degradation, mucus entrapment, limited epithelial permeability, active efflux, and hepatic first‐pass metabolism, all of which restrict systemic exposure. Recent advances in nanocarrier engineering and AI‐driven design are beginning to overcome these barriers through synergistic innovations in medicinal chemistry, formulation science, and clinically validated enhancer platforms. Mechanistic insights into gastrointestinal physiology have enabled the rational development of technologies such as SNAC and TPE, supporting gastric or intestinal transcellular uptake and establishing the first clinically approved oral peptide formulations. Parallel progress in peptide engineering including cyclization, D‐amino acid substitution, lipidation, and transporter‐targeted conjugation enhances proteolytic stability and epithelial interaction, while next‐generation polymer–lipid hybrids, mucus‐penetrating carriers, bile‐acid–guided systems, and stimuli‐responsive biomaterials provide tunable protection and controlled release across the GI tract. Device‐assisted platforms such as LUMI, SOMA, and RaniPill further expand this toolkit by bypassing epithelial barriers altogether. These technological gains intersect with sustainable manufacturing and green bioprocessing considerations essential for scalable clinical translation, along with persistent global health challenges in LMIC settings. Collectively, these developments highlight a decisive shift toward clinically viable, patient‐centric oral peptide therapeutics and outline a forward SDG‐aligned trajectory in which computational design, eco‐efficient production, and advanced biomaterial systems converge to enable reliable systemic and local delivery via the oral route.
- 20 March 2026
- Published by Wiley in Peptide Science
- Vol. 118 (3) , e70027
Engineering Peptides for Oral Delivery: Structural Design, Barrier Modulation, and Emerging Therapeutic Technologies
Oral delivery of peptide therapeutics remains a major challenge due to extensive enzymatic degradation, mucus entrapment, limited epithelial permeability, active efflux, and hepatic first‐pass metabolism, all of which restrict systemic exposure. Recent advances in nanocarrier engineering and AI‐driven design are beginning to overcome these barriers through synergistic innovations in medicinal chemistry, formulation science, and clinically validated enhancer platforms. Mechanistic insights into gastrointestinal physiology have enabled the rational development of technologies such as SNAC and TPE, supporting gastric or intestinal transcellular uptake and establishing the first clinically approved oral peptide formulations. Parallel progress in peptide engineering including cyclization, D‐amino acid substitution, lipidation, and transporter‐targeted conjugation enhances proteolytic stability and epithelial interaction, while next‐generation polymer–lipid hybrids, mucus‐penetrating carriers, bile‐acid–guided systems, and stimuli‐responsive biomaterials provide tunable protection and controlled release across the GI tract. Device‐assisted platforms such as LUMI, SOMA, and RaniPill further expand this toolkit by bypassing epithelial barriers altogether. These technological gains intersect with sustainable manufacturing and green bioprocessing considerations essential for scalable clinical translation, along with persistent global health challenges in LMIC settings. Collectively, these developments highlight a decisive shift toward clinically viable, patient‐centric oral peptide therapeutics and outline a forward SDG‐aligned trajectory in which computational design, eco‐efficient production, and advanced biomaterial systems converge to enable reliable systemic and local delivery via the oral route.